Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will experience debilitating bouts of depression – and often unexpectedly, their entire neurophysiology will shift to facilitate a state of mania (elevated mood). Diagnostically, there are multiple types …
Saphris (Asenapine) is a drug that was approved by the FDA in 2007 for the treatment of schizophrenia and the manic phases of bipolar disorder. It functions by acting primarily on 5-HT2A serotonergic receptors and D2 dopaminergic receptors as an antagonist. It also elicits effects on a variety of other serotonergic receptors (5HT2B, 5HT2C, 5HT6, …
Saphris (Asenapine) is an atypical antipsychotic medication that was approved in 2009 for the treatment of schizophrenia and bipolar disorder. It is a relatively new atypical antipsychotic, and is considered a chemical derivative of the tetracyclic antidepressant (TeCA) mianserin. It is manufactured in a sublingual format, which some may perceive as an upgraded or novel …